Johnson & Johnson's Q3 2023: Over $21.3B In Sales, 'Sharpened Focus' On Innovation & Biotech Solutions
Portfolio Pulse from Lara Goldstein
Johnson & Johnson (J&J) reported Q3 2023 financial results with total sales of $21.3 billion, a 6.8% increase compared to the same period in 2022. U.S. sales totaled $11.996 billion, an 11.1% increase from 2022. The company also reported a one-time, non-cash gain of around $21 billion related to the final separation of J&J’s consumer health business. The company received several treatment approvals from the FDA and the European Commission, and submitted applications to the European Medicines Agency.

October 17, 2023 | 6:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Johnson & Johnson reported strong Q3 2023 results with significant sales growth and regulatory approvals, which could positively impact its stock.
Johnson & Johnson's strong Q3 2023 results, with significant sales growth and regulatory approvals, indicate a positive business performance. This could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100